Characteristics | N (%) |
---|---|
Age (years) | |
 Median | 69 |
 Range, interquartile range | (37–86, 61–73) |
Gender | |
 Male | 21 (68) |
 Female | 10 (32) |
ECOG performance status | |
 0 | 13 (42) |
 1 | 16 (52) |
 2 | 2 (6) |
Primary tumor location | |
 Colon | 25 (81) |
 Rectum | 6 (19) |
Primary resected | |
 Yes | 26 (84) |
 No | 5 (16) |
No of metastatic site, | |
 1 | 10 (32) |
 2 | 9 (29) |
  ≥ 3 | 12 (39) |
Metastatic sites | |
 Liver | 22 (71) |
 Lung | 17 (55) |
 Lymph nodes | 13 (42) |
 Peritoneum | 9 (29) |
 Other | 4 (13) |
KRAS mutation | |
 Yes | 13 (37) |
 No | 18 (63) |
BRAF mutation | |
 Yes | 2 (6) |
 No | 26 (84) |
 Unknown | 3 (10) |
Number of lines prior therapy | |
 2 | 8 (19) |
 3 | 16 (59) |
  ≥ 4 | 7 (22) |
Median CEA level ng/ml (range, interquartile range) | 116 (0–42,230, 31–350) |
Median CA19-9 level ng/ml (range, interquartile range) | 222 (5–9820, 38–965) |